Evidence map›Paper›PMID 18155170›Full record

ReviewAdvances in enzyme regulation2008

Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Daniel E Johnson

Abstract readReview
In one paragraph

Review in Advances in enzyme regulation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Anti-leukemic principle(s) fromCytotechnology · 2022
    Article
  8. Article
  9. Article
  10. Imidazo[1,2-International journal of molecular sciences · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Daniel E JohnsonDivision of Hematology/Oncology, Department of Medicine, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15213-1863, USA. johnsond@pitt.edu

Funding

Opposing Roles for MEK/ERK in Differentiation &LeukemiaR01CA108904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHNSON, DANIEL E · 2005 to 2009
$1.4M
NCI NIH HHS R01 CA108904
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell DifferentiationExtracellular Signal-Regulated MAP KinasesHumansLeukemia, Myeloid, AcuteMAP Kinase Kinase KinasesMyeloid Progenitor Cellssrc-Family KinasesExtracellular Signal-Regulated MAP KinasesMAP Kinase Kinase Kinasessrc-Family Kinases

Identifiers

PMID18155170
PMCPMC2633125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.